Animal Friends is launching a pilot programme through which its customers will be able to check their pets' symptoms, get advice on treatment or find out if they need to visit a vet clinic on Joii.
Paul Hallett, co-founder of Vet-AI said: "Animal Friends is a perfect partner for Vet-AI, not only do we share common goals around animal welfare and the profession as a whole, but strategically we are both laser focused on the customer. In the coming few years we will support their customers by providing them with 24 hour expert-led care, at the click of a button. This will drive our business forward, helping us reach more pet owners and improve the care their pets receive."
Wes Pearson, Managing Director of Animal Friends said: "This partnership demonstrates our commitment to provide our pet parents with innovative options to ensure their pet receives the best care. Being able to access professional advice from the comfort of their own home and at a time that suits them can dramatically reduce stress for both the pet and the pet parent. We are excited to be working with Vet-AI and believe that the Joii app will bring expert knowledge and extra peace of mind to our customers."
Oh no, not another company talking about 'pet parents'. Is it just me, or is it not rather patronising?
The new maternity policy will offer enhancement at 100% of full pay for 10 weeks, and 50% of full pay for a further 10 weeks, without any clawback provision should mothers decide not to return to CVS after their leave.
As part of the Time To Change Pledge, CVS will submit a plan for introducing evidence-based interventions and policy to help its employees work in ways that promote positive mental wellbeing.
CVS's plan includes the appointment of 250 Wellbeing Champions who will be trained in first aid for mental health. The company also plans to roll out further training on managing stress and mental health issues for line managers in 2020.
Richard, pictured right, said: "We are proud to be the first major veterinary employer to sign the Time to Change Pledge. The CVS wellbeing working party have made much progress in the last 12 months delivering our plan which has been formalised through participating in the Time to Change pledge.
"We recognise that the pressures in our industry are significant and unique, and that there’s more work to do. We remain committed as a company and wellbeing working party to changing the way we all think and act about mental health in the workplace for the better."
It is not the first time Roundhouse Referrals has innovated in this area. Last year, it launched the first 'Fixed Price TPLO' - a guarantee that pet owners will have no additional costs, should complications arise and further treatment be required following surgery.
Ross Allan, RCVS Advanced Practitioner in Small Animal Surgery and Surgical Lead at Roundhouse Referrals, said: "We loved the idea of providing price certainty for referral clients, allowing those with no or lower levels of insurance to access our services and plan their finances. We also realised that in putting 'Fixed Price Fix' first and foremost we are also immediately highlight the possibility of complications and we felt the very best way to provide context for owners and referring vets would be to be open about our outcomes."
Following on from this Roundhouse Referrals has published the first of what it says will be a series of reports on TPLO+ clinical outcomes and customer satisfaction.
Ross said: "I think we're the first in Scotland to publish this kind of information outside scientific journals in a way that is easily accessible for pet owners, maybe in the whole of the UK."
The clinical outcome data was collected using a previously published questionnaire which enabled clients to give feedback on their pet’s recovery and status following their TPLO+ surgery.
According to Roundhouse, the results show that over 97% of dog owners rated their pets’ outcome as either excellent (85.29%) or good (11.76%) based on the first 70 TPLO+ surgeries performed. A figure which Ross says compares favourably with studies that have been previously published.
Additionally, 94.1% of pet owners agreed that if faced with having to make a similar decision again, they would choose to have the TPLO+ surgery done at Roundhouse Referrals, compared to 84.6% of owners in the previous study.
The results from the Customer Satisfaction Questionnaire showed that 100% of Roundhouse Referrals’ clients felt supported throughout the referral process, 96.97% of clients felt that the TPLO+ surgery was adequately explained and 100% would recommend Roundhouse Referrals to a friend or colleague.
Ross said: "Pet owners whose dogs’ had been through TPLO+ surgery and rehabilitation completed this questionnaire, enabling us to start measuring the outcome of the surgery, our aim being to ensure the surgery is optimal for the pet, and that owners feel supported throughout the entire surgical journey.
"We are delighted with these results, and will continue to monitor our outcomes and commit to publish our TPLO+ clinical outcome and customer satisfaction questionnaire results in the months and years ahead".
The winners and runners up will be honoured at a ceremony taking place on the eve of BSAVA Congress on 1st April 2020.
The television presenter Matt Baker will be hosting the Ceva Animal Welfare Awards for the third consecutive year, alongside head judge Chris Laurence MBE FRCVS, who puts his name to the Vet of the Year Award.
The award categories include:
Chris Laurence Vet of the Year – sponsored by Vet Record
Vet Nurse of the Year – sponsored by Agria Pet Insurance
Charity Team of the Year – sponsored by PDSA
Charitable Contribution of the Year – sponsored by Blue Cross
International Cat Care Welfare of the Year – sponsored by International Cat Care
Farmer of the Year – sponsored by R.A.B.I. and Farmers Guardian
Farm Educator of the Year – sponsored by NADIS and Farmers Guardian
Outstanding Contribution to Animal Welfare – sponsored by Your Dog and Your Cat magazines
To nominate someone, visit wwww.cevawelfare.com. They can come from all walks of life and will be assessed on the evidence provided in the original nomination.
Entries must be in by Tuesday 31 December 2019.
Neptra has been approved for the treatment of acute canine otitis externa or acute exacerbations of recurrent otitis caused by mixed infections of susceptible strains of bacteria sensitive to florfenicol (Staphylococcus pseudintermedius) and fungi sensitive to terbinafine (Malassezia pachydermatis), by the European Commission.
Mario Andreoli, Head of Marketing at Bayer Animal Health, said: "Otitis externa is a common disease in dogs and a leading cause why owners take their dog to a veterinarian.
"Neptra offers a key advantage, unlike competing products, it requires just one dose, administered by the veterinarian in the practice."
No at-home applications by the dog owner are required. The treatment stays in the hands of the vet who has full control over compliance.
Mario added: "With Neptra we provide a high-quality veterinary treatment that is convenient for the dog owner and ensures the well-being of dogs with a proper, effective application."
VetSurgeon understands the new product will be available in the UK in January 2020.
Royal Canin highlights that obesity is one of the most common diseases that veterinary professionals face, and impacts patients' quality of life1, as well as their life expectancy2,3. Compliance is a common challenge in weight loss and even those that successfully reach their ideal weight frequently regain weight later. It therefore makes sense, says the company, to focus on prevention as well as long term management for obese cats and dogs.
Caroline Burke, Royal Canin UK Weight Management Specialist said: "Obesity is one of the most common diseases that vets and nurses see in practice, and this webinar is the latest in our programme of education around weight management. Vets and nurses will have the opportunity to learn about how they can help prevent, as well as manage obesity in practice, allowing them to truly make a difference to the lives of their patients."
Alex added: "Obesity is an ever-growing issue for cats and dogs, understanding the risks and prevention techniques is paramount for both pet owners and industry experts.
"This webinar aims to suggest how a lifelong practice monitoring programme can be implemented for the prevention of obesity. Whilst also reviewing the outcomes of weight management and defining types of prevention techniques which can be implemented."
To register for the webinar, 'How to be proactive rather than reactive for effective, preventative obesity management’, visit: https://vetportal.royalcanin.co.uk/cpd/webinar/
References
The VetCompass study, which was based on the records of over 900,000 Westies under the care of UK first opinion veterinary practices in 2016, also found that ownership of Westies has fallen dramatically, to just a quarter of what it was a decade ago. Researchers found that the breed comprised only 0.43% of puppies born in 2015 compared to 1.69% of puppies born in 2004.
The average age of the Westies studied was a relatively elderly 7.8 years, suggesting an ageing population with fewer new puppies entering the population compared to other breed studies carried out by VetCompass.
The most common illnesses suffered by Westies were found to be dental disease (which affects 15.7% of Westies), ear disease (10.6%), overgrown nails (7.2%), allergic skin disorder (6.5%) and obesity (6.1%). Lower respiratory tract disease and cancer were the most common causes of death, with each accounting for 10.2% of deaths in the breed. Spinal cord disorders were the next biggest killer at 7.8%.
Other findings included:
Dr Dan O’Neill, Senior Lecturer and VetCompass researcher at the RVC, who was the main author of the paper, said: "With the ascent of social media as a dominant influencer of public opinion, ownership preferences for dog breeds are becoming increasingly polarised and susceptible to the whims of internet celebrity endorsement and advertising.
"Previously, preferences for dog breeds used to wax and wane gently over time. But VetCompass breed data now show rapid changes in preferences among breeds that create bubbles and troughs of demand that can have far-reaching implications for these breeds.
"Flat-faced (brachycephalic) breeds are currently the darling of the nation but this has created huge welfare problems for breeds such as the Pug and French Bulldog. And breeds such as the West Highland White Terrier and Cavalier King Charles have fallen sharply out of favour."
Camilla Pegram, Veterinary Epidemiologist and VetCompass researcher at the RVC, who co-authored the paper, said: "The most common disorders of Westies shown in this study are also common in the wider UK dog population. However, the breed does seem predisposed to lower respiratory tract disease which was a common cause of death in the Westie. Owners should be aware of this as their Westie ages.
"What is particularly interesting is the level of skin disorders, which although relatively high, are still lower than might have been predicted a decade ago. It is possible that the reduction in Westie ownership has relieved the pressure on breeders to breed from less healthy individuals to meet demand and therefore contributed to improved skin health within the breed. Paradoxically, reducing popularity may have led to better health in the Westies that are now being born."
Reference
In mid-September, the Association wrote to the RCVS expressing concern about the August extension to the temporary guidance.
In the latest update from the RCVS, the temporary measure has now been extended to 31 October but the flowchart and guidance have been updated to add some additional steps before a POM-V product can be prescribed remotely.
The BVA says that while it supported the original decision in March as a pragmatic solution and direct response to government restrictions surrounding Covid-19, it is now questioning the ongoing need for such a relaxation in the rules.
In the letter to the RCVS, the BVA also asked for a timeframe for the publication of the results of the RCVS survey of practices’ experiences of remote consulting and prescribing. The Association's own under care working group, chaired by Nigel Gibbens, has been developing a position to respond to the RCVS review.
BVA President James Russell (pictured right) said: "We understand that allowing remote prescription of POM-Vs was a necessary measure at the height of the lockdown, as practices struggled to assess patients in person.
"However, the veterinary professions have done a fantastic job in adapting to the restrictions and are now able to work safely and see patients.
"Whilst we recognise the RCVS has provided additional guidance for the remote prescribing of POM-V, we cannot currently see any reason why a new client would be unable to access in-person veterinary care in the first instance and we are asking RCVS Council to reconsider this measure when it meets in Oct.
"It makes sense to continue allowing vets to remotely prescribe for existing patients, for example if an owner is shielding, but we feel it is no longer appropriate to be remotely prescribing to animals that have never been physically examined by the vet.
“The question of whether we should be able to remotely prescribe POM-V products without first seeing an animal is an important and live debate, and we welcome the resumption of the College’s review. But the longer that temporary measures are in place, the greater the expectation from animal owners that they will always be in place, and the harder it will be to have the discussion about the best way forward.
“As a profession, we are rightly concerned about antimicrobial resistance and we pride ourselves on the responsible use of medicines. Continually extending the temporary measures without a full analysis would risk undermining our position.”
RCVS Council had introduced temporary guidance allowing the remote prescription of drugs for animals not under care back in March, to ensure that animal health and welfare could be maintained during lockdown without risking the health of veterinary teams or their clients.
Since then, the College has twice extended this guidance, because of the ongoing situation.
However the College says it now recognises that many practices are returning more to 'business as usual' and that the guidance and associated flowchart should be updated according.
Consequently, before deciding to prescribe POM-Vs remotely, the updated guidance now requires veterinary surgeons to first consider whether the animal is already under their care; or, if not, whether it is possible to physically examine the animal in order to bring the animal under their care. If the answer to both questions is ‘no’, POM-Vs may still be prescribed remotely providing the guidelines set out in the College’s coronavirus advice hub are adhered to.
Surprisingly, the College says that its surveys of the profession have thus far identified no immediate safety concerns around remote prescribing.
RCVS President Dr Mandisa Greene, who chairs the Taskforce, said: “The reason for maintaining the possibility of remote prescribing without a physical examination was that we recognised that the current situation is unpredictable, and while the ability for the public to visit practices in person has improved over the last few months, we felt that situations might still arise where that would not be possible, and where access to remote prescribing would be necessary. These could include further local lockdowns, ongoing quarantine arrangements, and the remaining fact that some members of both the veterinary team and the public continue to shield.
“It remains our intention that this guidance will continue to be a temporary measure and may be subject to further extensions or updates given the uncertain nature of the Covid-19 pandemic.”
RCVS Council will review the position on 8 October, with any changes being effective by 1 November at the earliest.
Meanwhile, the RCVS review of ‘under care’ and out-of-hours emergency cover has now resumed, starting with a number of virtual focus groups and consultation with stakeholders within the veterinary and veterinary nursing professions.
The findings from these focus group discussions will then inform a wider survey to be sent to all veterinary surgeons and veterinary nurses in early 2021, along with stakeholder organisations and the animal-owning public. Remote prescribing will continue to form a part of this review.
For the study, which was conducted in 2018 and published this year in Medical and Veterinary Entomology1, practices from around the UK sent in combings from 812 cats and 662 dogs for analysis.
28% of the cats and 14% of the dogs were found to be carrying fleas, with cats from central Wales and the Welsh Borders being more than twice as likely to have fleas than elsewhere in the country. Likewise, dogs from North Wales, the North Wales borders, South Wales and South West England were between 3 and 4.5 times as likely to have fleas as elsewhere.
Of the cats treated with fipronil, 62% (n=57) were still found to be carrying fleas despite treatment. Of the dogs, 44% (n=49) of those treated with fipronil were still carrying fleas. By contrast, 4.1% of cats and 1.4% of dogs treated with fluralaner (Bravecto) were found to have fleas (the lowest of any treatment).
Professor Richard Wall, Veterinary Entomologist at the University of Bristol said: "There is a clear need for greater owner education about the importance of flea treatment and a better understanding of the efficacy of different flea and tick prevention products.
"It is critical for vets to not only recommend the best product for a pet’s needs but to also give a better understanding of the effectiveness and correct application of the different treatments."
Photo: Professor Richard Wall, University of Bristol
Thiamacare contains 10 mg/ml thiamazole, which is double the concentration of Thyronorm, for a lower dose volume.
Animalcare highlights research which shows that 87.4% of owners prefer liquid medications for their cat1, and that cats find liquid presentations more palatable2.
James Beaumont from Animalcare said: "With the lowest dose volume available, we believe Thiamacare will make the medical management of this condition easier through improved cat acceptance and better owner compliance."
Thiamacare's dosing syringe is marked with a single scale in 1.25 mg increments to facilitate precise dosing in response to total T4 measurement values. The scale does not need converting when switching from other brands or formulations.
Animalcare has developed a range of supporting materials to encourage the use of Thiamacare as the preferred choice for feline hyperthyroid medical management. They include social posts and a post-prescription leaflet to help veterinary teams support owners, particularly through the stabilisation phase post-diagnosis.
A short webinar offering top tips for treating feline hyperthyroidism from feline Specialist Dr Caney will also be available later in October. These resources will all be available at www.the-pac.co.uk.
The service will be run by European and RCVS recognised specialist in Soft Tissue Surgery, Jane Ladlow, and will begin taking referrals from October 28th.
Jane has nearly 20 years’ experience as a specialist clinician, researcher, teacher and lecturer.
Her main focus for the last 10 years has been upper airway disease in dogs. As the clinical lead of the Cambridge Brachycephalic Obstructive Airway Syndrome (BOAS) Research Group, she has been instrumental in the introduction of objective, non-invasive assessments of airway function, identifying risk factors for BOAS, clinical diagnosis, breeding guidelines and the development of new surgical techniques (laser turbinectomy and laryngeal surgeries).
She has extensive experience of general surgery, and particularly enjoys oncology surgery, with an emphasis on treatments that are kind to owners and animals. Jane was the 2019 recipient of the BSAVA Simon Award for outstanding contributions in the field of veterinary surgery.
Jane said, “The team at HSR demonstrate a drive for excellence, both clinically and in providing the best experience for clients and their pets. I’m excited to start working as part of the innovative and collaborative team of surgeons, nurses and support staff.”
Director and orthopaedic surgery specialist, Michael Hamilton, said: “We’re absolutely delighted to welcome Jane to the team here. Her work has revolutionised the way we diagnose and manage BOAS. Continual learning and innovation are core to our practice, and we know Jane will be a strong driving force helping us continue providing the best outcomes for clients and their pets.”
For more information, visit: www.hamiltonspecialists.vet
Propomitor can be used for the induction and maintenance of general anaesthesia for procedures lasting up to five minutes by the administration of incremental doses or as a constant rate infusion (CRI).
It can also be used for the induction of general anaesthesia where maintenance is provided by the inhalation of anaesthetic agents.
Animalcare Product Manager Kai Crawshaw said: "Propofol is the ‘go to’ solution for short-acting anaesthesia in many practices so we are delighted to add Propomitor, our new affordable propofol solution, to our range. It complements our already extensive anaesthetic toolkit, which offers options for analgesia, sedation, gaseous anaesthesia and recovery."
Propomitor is available in boxes of 5 x 20 ml bottles.
For more information, contact your Animalcare Territory Manager or Animalcare’s head office on 01904 487687.
The university says that new resource, which is aimed at qualified and student nurses, will provide fresh perspectives on the interactions between nursing care, animal health and patient behaviour and how the overlap between these things can improve patient welfare and clinical outcomes.
Topics covered include clinical skills, patient handling and behaviour, wound management and bandaging, animal welfare and inpatient care. Content includes video tutorials, downloadable fact sheets and interactive quizzes.
The Royal (Dick) School’s Welfare and Anaesthesia Nurse Hayley Walters, who teaches final year vet students, said: “Knowledge and compassionate veterinary nurses improve patient welfare, so we want to share some of our educational and animal welfare expertise with a global audience.
"This new resource will help to promote the role of the veterinary nurse as a para-professional who is an essential part of the veterinary team."
For more information or to register, visit: https://www.ed.ac.uk/vet/jeanne-marchig-centre/cpd/vnos
For the 10,000 steps challenge, the practice has split into teams of eight which will compete against each other for a weekly prize for the team that collectively walks the furthest.
The practice is also encouraging colleagues to participate in daily wellbeing sessions, including interval training and a mindfulness programme, in conjunction with healthcare partner Vitality.
Mark Goodfellow, Head of Oncology at Davies and Mental Health First Aider said: “Commitment to high standards and dedication to patient care can lead to long working hours.
"Couple this with sick patients, distressed clients and end of life decision-making and the outcome can be feelings of failure, hopelessness and compassion fatigue.
"Simply taking time to walk and share experiences with a colleague can be an unburdening in itself. A problem shared with the right person is a problem halved.”
The announcement came in the form of a written statement by the then Home Secretary Sajid Javid to the House of Commons on 23rd July, which said: "The Government is happy to accept all of the MAC’s recommendations on the composition of the SOL and the necessary amendments will be made in the Autumn Immigration Rules changes."
Being on the shortage occupation list means that employers do not need to advertise jobs for veterinary surgeons in the UK for 28 days before advertising abroad (the Resident Labour Market Test). In addition, there are lower visa fees and it provides exemption from the minimum income threshold.
RCVS President Niall Connell said: "Both the Royal College of Veterinary Surgeons and the British Veterinary Association worked together to ensure this outcome, which will see a lowering of the immigration barriers, for example, in terms of visa requirements, for overseas veterinary surgeons who wish to live and work in the UK.
"We also considered this a vital piece of preparation for the UK leaving the EU, as around half of those registering as veterinary surgeons with the RCVS in a given year are non-UK EU nationals and we would not want to see this vital supply of veterinary talent immediately dry up should ‘freedom of movement’ end when the UK leaves the EU.
"We thank Mr Javid for accepting the Committee’s proposals and congratulate his successor Priti Patel on her appointment and look forward to the decision being implemented. The new Prime Minister pledged on the steps of Downing Street to do more to promote the welfare of animals, and having veterinary surgeons on the Shortage Occupation List will help in our mission to uphold animal health and welfare and ensure that vital veterinary work can continue to get done, whatever happens with the relationship between the UK and the EU."
Open to anyone working in a veterinary setting at any stage of their career, the competition rewards teams and individuals (clinical and non-clinical), who have achieved better outcomes through QI initiatives for patients, clients, the business or the working environment.
Individual winners will be crowned 'Knowledge Champions' and one team will become RCVS Knowledge’s 'Champion Practice'.
Each winner will also receive a £250 reward, tickets to the awards ceremony next calendar year and the opportunity to work with RCVS Knowledge to further promote their quality improvement work.
Candidates can nominate themselves or others for an award.
If you want to nominate a colleague, the deadline is 17thOctober. The deadline to apply on your own behalf or that of your team/practice is 29th November 2019.
Full details are available online: bit.ly/KnowledgeAwards.
Executive Director of RCVS Knowledge, Chris Gush said: "The 2019 awards shed light on the very good work those in the profession are doing to continually enhance quality, so we are delighted to bring the competition back for 2020.
"It is a great opportunity for individuals and teams to showcase their quality improvement initiatives. Whether it is clinically focused or aiming to improve procurement, we are keen to hear about the work that is underway."
Last year's awards highlighted inspirational QI projects such as a drugs audit that led to a ten-fold improvement in usage discrepancy; a quarterly clinical audit that enhanced nursing expertise and trust from veterinary surgeons; and the introduction of guidelines that coincided with the subsequent treatment of 2,639 additional animals.
The case examples submitted by each winner are available to download for free:
'Champion Practice' Vets Now Macclesfield for its anaesthesia audit.
'Knowledge Champion' Louise Northway RVN, Wendover Heights Veterinary Centre, for her anaesthesia audit.
'Knowledge Champion' Alison Thomas MRCVS, Blue Cross, for her case study: Creating clinical guidelines.
'Knowledge Champion' Angela Rayner MRCVS, CVS Group plc, for her case study: Controlled drugs process audit.
For more case examples and QI resources, visit: bit.ly/QIKnowledge
The Disciplinary Committee heard three charges against Dr Dhami, relating to events which took place while he was in practice at Vets4Pets in Market Harborough, Leicestershire.
The first charge against him was that, in November 2017, he used excessive force in kicking and stamping on a Staffordshire Bull Terrier he was treating.
The second charge was that, between in October and November 2017, he failed to pay adequate regard to the welfare of a Jack Russell in his care by leaving it in a sink without adequate reason and for an excessive period of time.
The third charge was that, between April and March 2018, he failed to have adequate regard to the welfare of a six-to-eight week old kitten, including providing bedding and warmth.
At the outset of the hearing Dr Dhami admitted to lightly kicking the dog, but denied forcefully kicking it and also denied that he had stamped on the dog, as well as denying the other two charges against him.
In considering the circumstances of the first charge, the Committee heard evidence from two of Dr Dhami’s colleagues stating that the dog had bitten him whilst he was cleaning its ears and, following this, he took the dog out of the consulting room, closed the door and whilst holding the dog’s lead then proceeded to kick her twice, knocking her along the floor both times, and then finally stamp on her when she was prone.
Dr Dhami disputed his colleagues' version of events and stated that he had only delivered two light kicks to the dog’s rump, that neither of these had made her fall to the floor and also denied in categorical terms that he stamped on the animal. Furthermore, he also denied the second and third charges against him.
In considering the evidence as to whether Dr Dhami kicked and stamped on the dog, the Disciplinary Committee found the evidence of his two colleagues to be credible and reliable, and so found all aspects of the charge proven.
Ian Green, chairing the Committee and speaking on its behalf, said: "For the avoidance of doubt, the Committee finds that the admitted kicks administered to [the animal] by the respondent were of significant force. The Committee rejects the respondent’s assertion that the admitted kicks amounted to mere taps on the backside. The Committee finds that the ‘stamping’ was also of significant force."
In regards to the second and third charges, the Committee was not satisfied that the charges had been proven by the evidence it heard and therefore dismissed them both.
Having found all parts of the first charge proven, the Committee then went on to consider whether or not Dr Dhami’s conduct amounted to serious professional misconduct, something that Dr Dhami, following the Committee’s decision on the facts, through his counsel, had admitted.
The Committee identified a number of aggravating factors, including the real risk of physical harm to the animal and the deliberate nature Dr Dhami’s conduct against the animal, committed in anger.
In mitigation, the Committee accepted that this was an isolated incident and that Dr Dhami had been bitten and was in pain. The Committee therefore found that Dr Dhami’s admission of serious professional misconduct was ‘properly and prudently made’.
The Committee then considered what sanction to impose on Dr Dhami. In doing so it took into account some of the written testimonials and character witnesses called on behalf of Dr Dhami. The Committee was also satisfied that Dr Dhami had had a hitherto long and unblemished career, that he had apologised to colleagues immediately after the incident and that, since the events, he had continued to work as a veterinary surgeon without any problems.
In relation to insight about the event, the Committee accepted Dr Dhami had provided some evidence of reflection, in that he admitted kicking the dog and accepted that this conduct, once found proven, amounted to serious professional misconduct.
The Committee decided that suspending Dr Dhami from the Register for four months would be the most proportionate sanction.
Ian Green concluded: "Having regard to all the matters urged by way of mitigation, and having taken into account all the evidence that it has heard, the Committee is satisfied that a period of suspension is sufficient in this case to protect the welfare of animals, maintain public confidence and to declare and uphold proper standards of conduct."
Dr Dhami has 28 days from being informed of the outcome of the hearing in which to make an appeal to the Privy Council.
The company points to a study which showed that cats treated Bravecto Plus showed no visible signs of mites at 14 days and 100% efficacy was confirmed at 28 days1. This, says the company, means that Bravecto Plus now gives 12 week control of fleas and ticks, eight week prevention of heartworm disease, treatment of roundworm and hookworm, and treatment of ear mites.
Hannah Newbury, Companion Animal Technical Lead at MSD Animal Health said: "With 1 in 4 cats in the Big Flea Project study having fleas2, we can conclude that pet owner compliance to parasite prevention is currently poor.
"This new licence is an important development for vets and cat owners, offering greater convenience, while helping improve flea and tick compliance. Bravecto Plus builds on the qualities of Bravecto and offers vets and cat owners another tool in the fight against an even broader range of potentially harmful parasites.
"Research by MSD Animal Health shows that 82% of cat owners believe that the ideal flea and tick treatment lasts longer than 2 months3 and vets can offer their cat owners this and more with BRAVECTO PLUS due to its 12 week duration of activity4.
For further information contact your MSD Animal Health Account Manager.
Amy Scott MRCVS, Boehringer Ingehlheim’s performance horse portfolio manager, said: "Arti-Cell Forte is the first 'ready-to-use' stem cell-based product to be licensed in any veterinary species, and the only stem cell treatment to contain induced cells, representing a significant leap forward in both stem cell therapies and medicine as a whole.
"Arti-Cell Forte contains stem cells that have been chondrogenically induced and therefore primed to develop into the cartilage cell lineage. Studies have shown that chondrogenically induced stem cells demonstrate an enhanced clinical outcome compared to un-induced stem cells in the treatment of joint disease in horses¹."
"This makes Arti-Cell Forte a highly targeted and effective treatment for cartilage damage associated with degenerative joint disease."
Arti-Cell Forte is available direct from Boehringer Ingelheim to veterinary practitioners.
It needs to be stored at ultra-low temperatures to maintain its two year shelf life from manufacture, either frozen at -70 ⁰C to -90 ⁰C (dry ice, -80 ⁰C freezer) or -196 ⁰C (liquid nitrogen) until immediately prior to injecting.
The company is providing full training on storage and administration via face-to-face CPD at practice meetings or specific CPD events*.
For more information, contact your local territory manager or ring Boehringer's Technical Services Team on 01344 746957, or email vetenquiries@boehringer-ingelheim.com
The Disciplinary Committee had found Dr Schulze Allen guilty of four charges, namely that he had been convicted of the criminal offence of petty theft in the US which rendered him unfit to practise, and that on three subsequent occasions, twice to the RCVS and once to a notary in California, dishonestly represented that he had no criminal convictions.
Following the DC hearing, Dr Schulze Allen submitted an appeal to the Privy Council. The basis of his appeal revolved around whether, under Californian law, his conviction for petty theft was a conviction for a criminal offence or an infraction, and whether an infraction under US law was a criminal offence.
The RCVS had argued that while the theft is not a criminal felony in California, it would be considered so under English law.
However, the Board of the Privy Council which heard the appeal – comprising Lords Wilson, Carnwath and Lloyd-Jones, found the College had not proven beyond all reasonable doubt that Dr Schulze Allen was convicted of a criminal offence under Californian law. It therefore upheld his appeal against the DC’s finding that he had committed a criminal offence.
The Privy Council then considered Dr Schulze Allen’s appeal against the third and fourth of the charges against him - that he was dishonest in his representations to the College that he did not have a ‘criminal’ conviction and did not have a ‘criminal record’. The Privy Council found that, since the conviction for petty theft was an infraction, and was not a criminal offence and did not leave Dr Schulze Allen with a criminal record, then, strictly speaking, his representations to the RCVS were not false and so upheld his appeal against these two charges.
The Privy Council then considered Dr Schulze Allen’s appeal against the College’s second charge against him. This charge was that he had, in a written application for restoration to the Register, represented that he did not have any cautions, criminal convictions or "adverse findings". The College argued that he still had a responsibility to make a full and frank disclosure about his infraction, even if it did not meet the threshold of ‘criminal’ under Californian law.
The Board of the Privy Council said it had, on Dr Schulze Allen’s behalf, done its best to identify some argument that his conviction for a petty theft infraction did not amount to an "adverse finding", but failed. Rather, it found that "the conviction obviously amounted to an adverse finding."
The Board added that "there is no material by reference to which the Board [of the Privy Council] can depart from the [Disciplinary] Committee’s conclusion that, in answering “no” to that question, he knew that his answer was untrue. In other words, his denial was dishonest."
The Board therefore allowed the appeal against the DC’s conclusion on the first, third and fourth charges. But it dismissed the appeal against its conclusion on the second charge, namely that in that regard Dr Schulze Allen had been guilty of disgraceful conduct in a professional respect."
The Board then set aside the original sanction, that Dr Schulze Allen be removed from the Register, and tasked the Committee with identifying the appropriate sanction in relation to the second charge.
The Disciplinary Committee will now hold a further hearing to decide the sanction, at some time in the future. In the meantime Dr Schulze Allen remains on the Register of Veterinary Surgeons.
Vetemex has a 56-day broached shelf life and uses benzyl alcohol as the excipient, rather than metacresol.
Virbac points to a study in which benzyl alcohol achieved a 78% reduction in pain score immediately post-injection, and a 53% reduction in pain score in the 2-minute period post-injection, compared to Metacresol1.
Vetemex is presented in a 20ml bottle and is available from the veterinary wholesalers now.
Claire Lewis, Product Manager at Virbac said: "Vetemex is a valuable addition to the already extensive Virbac portfolio. We are pleased to be able to offer vets this new, and more comfortable to administer, antiemetic option."
For more information on Vetemex, speak to your Virbac Territory Manager.
The charity says that although histiocytic sarcoma is rare, it is an aggressive form of cancer which Flatcoated Retrievers are particularly susceptible to.
According to the AHT, almost half of all affected Flat-coated Retrievers will have a tumour in multiple locations in the body at the time of diagnosis. The outlook for these dogs is very poor and, in most cases, means they receive a terminal diagnosis.
The new research revolves around microRNAs, abnormal levels of which are often found in tumours. In addition, different microRNAs are involved in different cancers. These cancer-specific microRNA signatures can be found within the blood of cancer patients, meaning that a tumour could potentially be diagnosed with a blood test.
To start with, the researchers say they plan to confirm if there is a specific microRNA signature that is unique to histiocytic sarcomas amongst tumours and normal tissue samples from Flatcoated Retrievers. If a signature is identified, the project will investigate if measuring the levels of these microRNAs within a Flatcoated Retriever tissue sample can be used to accurately identify a histiocytic sarcoma. If it can, additional funding will be sought for more research to identify if the microRNA signature is also detectable in the blood of affected dogs, and thence to develop a blood test.
If it comes off, this would mean that a blood sample from a Flatcoated Retriever that was lame, or was showing non-specific clinical signs of the disease such as depression, lethargy, appetite or weight loss, could be tested for the presence of the histiocytic sarcoma-associated microRNAs.
A dog with a positive test result could then have an early MRI scan and histopathology done to confirm the diagnosis, hopefully at a stage where treatment would be more successful.
Dr Anna Hollis, cancer researcher at the Animal Health Trust, said: "I have Flatcoated Retrievers and have lost one of them to histiocytic sarcoma - it is absolutely devastating. This research could make a significant difference, and that is a huge personal motivation for me. Histiocytic sarcoma is a particularly tricky cancer to diagnose, because the tumours are frequently located deep within or between the muscles of the upper limbs - underneath the shoulder is a common location.
"Often lame dogs are rested and given pain relief before imaging is sought. Delayed diagnosis is a potential problem with histiocytic sarcoma given its aggressive nature and ability to spread rapidly to other locations within the body. If we could identify affected dogs at an earlier stage, this may allow more successful treatment of the disease."
The research project has been funded by the Flatcoated Retriever Society (FCRS) and the FCRS Rescue, Rehousing and Welfare Scheme. The Flatcoated Retriever Breed Health Co-ordinator, Liz Branscombe, said "Sadly, there is a high incidence of this aggressive form of cancer in our beautiful breed. Early detection of the disease is key in optimising cancer treatment and prolonging survival time so the prospect of a diagnostic blood test for use in the future is exciting.'
Photo: Liz Branscombe, Dr Mike Starkey and Dr Anna Hollis of AHT and Brian Jones of FCRS Rescue, Rehousing and Welfare.
The company says the new test overcomes a major shortcoming in faecal egg counts: that they can only detect the presence of egg-laying adult worms. The new test, by contrast, can detect all stages of the small redworm life cycle, including the important encysted larval phase.
ADB says the new test will help protect the effectiveness of moxidectin, the only dewormer which is capable of eliminating the encysted stages and against which widespread resistance is not thought to have developed.
Whereas before, routine winter treatment was needed to target the encysted phase, this new test means the drug can be kept for when it is really needed, which will help prevent the development of resistance. ADB says it will also be of great value to equine vets in making differential diagnoses.
The blood test was developed by Prof Jacqui Matthews’ group at the Moredun Research Institute (MRI), with funding from The Horse Trust. She said: "It is great to see the commercialisation of this much-needed test to support sustainable worm control in horses. The test fills an important gap in our diagnostic toolbox and will enable horse owners to work with their veterinarians in targeting anthelmintic treatments against cyathostomin infections and hence help protect these important medicines for the future."
Dr Corrine Austin from ADB said: "ADB is now developing laboratory ELISA kits to enable independent veterinary laboratories to conduct blood testing; these kits are expected to reach market during 2020. Research into the saliva-based test is ongoing and is expected to be commercialised several years from now."
Veterinary practices can contact ADB at info@austindavis.co.uk to register interest in the diagnostic test service.
The poster grades faeces from one (kickable) to six (most certainly not kickable).
James Kyffin, Veterinary Director at Protexin Veterinary said: "We believe that Poop Points offers pet owners a fun and engaging way to monitor their pet’s faeces."
That, surely, must win James the "Oxymoronic Veterinary Quote of the Year Award 2019".
More seriously, he went on to say: "It is important to raise awareness of alterations in animal’s faecal scores and ensure that this is communicated to their veterinary surgeon in an effective way."
Practices in the UK and Ireland can order their free poster on Protexin's website: https://www.protexinvet.com/pooppoints, or by emailing info@protexin.com.
Protexin will also be promoting digestive health advice on its website and social channels (@Protexin Veterinary on Facebook and Instagram), which practices can share and use.